Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare ConferenceWARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ...

Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies

SHANGHAI and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced today the ...
Seeking Alpha

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc (MXCT)., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, ...
GEN

Scaling Cell Therapy Development from Research to Commercialization

Nik Ekman is the application development manager for Cell & Gene Therapy covering the Americas at CPC. Ekman has 10 years of experience in applications engineering and process development within the ...

Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 ...

Cell and gene therapies present promising opportunities, especially in oncology, blood disorders, and neurology. Investors prioritize scalable platforms and clear regulatory paths. Focus has shifted ...
MarketWatch

TreeFrog Therapeutics Presents Delivery Strategy for Next Generation 3D Cell Therapy Format for Parkinson's Disease at the 28th Annual ASGCT Meeting in New Orleans

The MarketWatch News Department was not involved in the creation of this content. TreeFrog Therapeutics Presents Delivery Strategy for Next Generation 3D Cell Therapy Format for Parkinson's Disease at ...
Labroots

Unlock Cell Therapy Potential with Customizable Cell Isolation and Enhanced T cell Activation Solution

Cell isolation and activation are critical for cell therapy development and manufacturing. Ease of use, regulatory compliant and financial sustainability are among the most important considerations.
Nasdaq

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy ...

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, ...
Business Wire

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted nine ...
Morningstar

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline Company’s Phase 1/2 Clinical ...
Nasdaq

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., ...